Vol 45, No 3 (2007)
Original paper
Submitted: 2011-12-19
Published online: 2007-10-24
Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Miroslaw Kozlowski, Oksana Kowalczuk, Anetta Sulewska, Piotr Dziegielewski, Grzegorz Lapuc, Wojciech Laudanski, Wieslawa Niklinska, Lech Chyczewski, Jacek Niklinski, Jerzy Laudanski
Folia Histochem Cytobiol 2007;45(3):199-204.
Vol 45, No 3 (2007)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2007-10-24
Abstract
Esophageal carcinomas have been shown to express Fas ligand (FasL) and down-regulate Fas to escape from host immune surveillance. Circulating soluble FasL (sFasL) has been suggested to provide protection from Fas-mediated apoptosis. The aim of this study was to assess serum sFasL levels in esophageal cancer. The pretreatment levels of sFasL in the serum of 100 patients with esophageal squamous cell cancer and 41 healthy volunteers were determined by ELISA. Probability of survival was calculated according to the method of Kaplan-Meier. The prognostic influence of high and low level of sFasL was analyzed with the log-rank test. The mean serum level of sFasL in patients with esophageal cancer was significantly higher than that in healthy donors (1.567+/-1.786 vs 0.261+/-0.435, p<0.0001). The levels of serum sFasL were significantly higher in advanced stages (II vs IV p<0.034; III vs IV p<0.041; except II vs III p=0.281), patients with lymph node (N0 vs N1 p<0.0389) or distant (M0 vs. M1 p<0.0388) metastases and significantly lower in patients with well differentiated tumors (G1 vs G2 p<0.0272). The serum levels of soluble FasL were not related to gender, age, tumor size, T-stage, tobacco smoking and history of chronic alcohol intake. The survival difference between pretreatment high and low level of sFasL in surgery and chemio- and/or radiotherapy group was not statistically significant (p=0.525; p=0.840). Our results indicate that elevated serum sFasL levels might be associated with a disease progression in patients with esophageal squamous cell carcinoma.
Abstract
Esophageal carcinomas have been shown to express Fas ligand (FasL) and down-regulate Fas to escape from host immune surveillance. Circulating soluble FasL (sFasL) has been suggested to provide protection from Fas-mediated apoptosis. The aim of this study was to assess serum sFasL levels in esophageal cancer. The pretreatment levels of sFasL in the serum of 100 patients with esophageal squamous cell cancer and 41 healthy volunteers were determined by ELISA. Probability of survival was calculated according to the method of Kaplan-Meier. The prognostic influence of high and low level of sFasL was analyzed with the log-rank test. The mean serum level of sFasL in patients with esophageal cancer was significantly higher than that in healthy donors (1.567+/-1.786 vs 0.261+/-0.435, p<0.0001). The levels of serum sFasL were significantly higher in advanced stages (II vs IV p<0.034; III vs IV p<0.041; except II vs III p=0.281), patients with lymph node (N0 vs N1 p<0.0389) or distant (M0 vs. M1 p<0.0388) metastases and significantly lower in patients with well differentiated tumors (G1 vs G2 p<0.0272). The serum levels of soluble FasL were not related to gender, age, tumor size, T-stage, tobacco smoking and history of chronic alcohol intake. The survival difference between pretreatment high and low level of sFasL in surgery and chemio- and/or radiotherapy group was not statistically significant (p=0.525; p=0.840). Our results indicate that elevated serum sFasL levels might be associated with a disease progression in patients with esophageal squamous cell carcinoma.
Title
Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Journal
Folia Histochemica et Cytobiologica
Issue
Vol 45, No 3 (2007)
Article type
Original paper
Pages
199-204
Published online
2007-10-24
Page views
1462
Article views/downloads
1330
Bibliographic record
Folia Histochem Cytobiol 2007;45(3):199-204.
Authors
Miroslaw Kozlowski
Oksana Kowalczuk
Anetta Sulewska
Piotr Dziegielewski
Grzegorz Lapuc
Wojciech Laudanski
Wieslawa Niklinska
Lech Chyczewski
Jacek Niklinski
Jerzy Laudanski